Wall Street brokerages expect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will announce earnings per share (EPS) of ($1.60) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Agios Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.65) and the highest is ($1.54). Agios Pharmaceuticals reported earnings of ($1.56) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 2.6%. The firm is scheduled to announce its next earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.15) per share for the current fiscal year, with EPS estimates ranging from ($6.51) to ($5.60). For the next year, analysts expect that the company will report earnings of ($4.42) per share, with EPS estimates ranging from ($6.00) to ($0.01). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). The company had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $12.65 million. Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. Agios Pharmaceuticals’s quarterly revenue was down 56.7% compared to the same quarter last year. During the same period last year, the firm earned ($1.34) earnings per share.
In related news, insider Christopher Bowden sold 2,000 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $77.65, for a total transaction of $155,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Carman Alenson sold 2,150 shares of the company’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $75.00, for a total transaction of $161,250.00. Following the transaction, the insider now owns 2,150 shares of the company’s stock, valued at approximately $161,250. The disclosure for this sale can be found here. Over the last three months, insiders have sold 185,114 shares of company stock worth $14,021,325. Corporate insiders own 5.43% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Alkeon Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $30,489,000. UBS Asset Management Americas Inc. raised its position in shares of Agios Pharmaceuticals by 965.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 345,284 shares of the biopharmaceutical company’s stock worth $19,740,000 after purchasing an additional 312,878 shares during the last quarter. First Trust Advisors LP raised its position in shares of Agios Pharmaceuticals by 26.3% during the 4th quarter. First Trust Advisors LP now owns 813,647 shares of the biopharmaceutical company’s stock worth $46,516,000 after purchasing an additional 169,331 shares during the last quarter. OppenheimerFunds Inc. raised its position in shares of Agios Pharmaceuticals by 679.7% during the 4th quarter. OppenheimerFunds Inc. now owns 142,283 shares of the biopharmaceutical company’s stock worth $8,134,000 after purchasing an additional 124,035 shares during the last quarter. Finally, Lord Abbett & CO. LLC raised its position in shares of Agios Pharmaceuticals by 81.5% during the 2nd quarter. Lord Abbett & CO. LLC now owns 266,910 shares of the biopharmaceutical company’s stock worth $13,733,000 after purchasing an additional 119,836 shares during the last quarter. Hedge funds and other institutional investors own 84.04% of the company’s stock.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded up $3.12 on Tuesday, hitting $81.81. 772,200 shares of the stock were exchanged, compared to its average volume of 780,764. The stock has a market capitalization of $4,690.00, a price-to-earnings ratio of -12.14 and a beta of 2.12. Agios Pharmaceuticals has a 12-month low of $45.11 and a 12-month high of $83.92.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.